Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Express Scripts
Baxter
Dow
Merck

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR RIPRETINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ripretinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02571036 ↗ A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Active, not recruiting Deciphera Pharmaceuticals LLC Phase 1 2015-10-01 This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.
NCT03353753 ↗ Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies Active, not recruiting Deciphera Pharmaceuticals LLC Phase 3 2018-02-27 This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo
NCT03673501 ↗ A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Active, not recruiting Deciphera Pharmaceuticals LLC Phase 3 2019-02-11 This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).
NCT04282980 ↗ A Study of DCC-2618 (Ripretinib) Evaluating Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Active, not recruiting Zai Lab (Shanghai) Co., Ltd. Phase 2 2020-04-23 The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.This study will enroll approximately 35 subjects in up to 10 sites in China mainland, and all subjects will be receiving DCC-2618 after enrollment as treatment.
NCT04530981 ↗ A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST Recruiting Deciphera Pharmaceuticals LLC Phase 1 2021-09-01 Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
NCT04633122 ↗ A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib Recruiting Zai Lab (Shanghai) Co., Ltd. Phase 2 2020-11-25 the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ripretinib

Condition Name

Condition Name for Ripretinib
Intervention Trials
Gastrointestinal Stromal Tumors 6
GIST - Gastrointestinal Stromal Tumor 1
Advanced Cancers 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ripretinib
Intervention Trials
Gastrointestinal Stromal Tumors 9
Mastocytosis 1
Neoplasms 1
Gastrointestinal Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ripretinib

Trials by Country

Trials by Country for Ripretinib
Location Trials
United States 53
China 19
Canada 8
Australia 6
Germany 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ripretinib
Location Trials
Florida 5
New York 4
Texas 4
Pennsylvania 3
Oregon 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ripretinib

Clinical Trial Phase

Clinical Trial Phase for Ripretinib
Clinical Trial Phase Trials
Phase 3 2
Phase 2 2
Phase 1/Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ripretinib
Clinical Trial Phase Trials
Active, not recruiting 4
Recruiting 3
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ripretinib

Sponsor Name

Sponsor Name for Ripretinib
Sponsor Trials
Deciphera Pharmaceuticals LLC 5
Zai Lab (Shanghai) Co., Ltd. 2
RenJi Hospital 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ripretinib
Sponsor Trials
Industry 8
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Johnson and Johnson
Merck
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.